Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.55 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235507 | 1.00 | LPAR3 (0.55) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| SCHEMBL29758206 | 0.98 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LPAR5SMPD1 | |
| SCHEMBL31235522 | 0.98 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LPAR5SMPD1 | |
| SCHEMBL31235649 | 0.98 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LPAR5SMPD1 | |
| SCHEMBL29758203 | 0.98 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LPAR5SMPD1 | |
| SCHEMBL29758212 | 0.98 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LPAR5SMPD1 | |
| SCHEMBL31235485 | 0.98 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LPAR5SMPD1 | |
| SCHEMBL31235531 | 0.94 | LPAR3 (0.53) | LPAR3LPAR2LPAR1LPAR5SMPD1 | |
| SCHEMBL15415958 | 0.94 | CYP3A4 (0.46) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL31235530 | 0.92 | LPAR3 (0.52) | LPAR3LPAR2LPAR1LPAR5SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4524217-A1 | ALKYL PHOSPHINATE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Liside New Material Co., Ltd. (CN) | 2025-03-19 | — | — | EP | claimed |
| US-20240309029-A1 | ALKYL PHOSPHINATE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU LISIDE NEW MATERIAL CO., LTD (CN) | 2024-09-19 | — | — | US | claimed |
| EP-4524217-A1 | ALKYL PHOSPHINATE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Liside New Material Co., Ltd. (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20240309029-A1 | ALKYL PHOSPHINATE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU LISIDE NEW MATERIAL CO., LTD (CN) | 2024-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309029-A1 | ALKYL PHOSPHINATE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | PHOSPHO1, PFAS, PLCG2 | LPAR3 2735/4885LPAR2 2998/4885LPAR1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.